Comparative treatment costs of risk‐stratified therapy for childhood acute lymphoblastic leukemia in India

Background To evaluate the treatment cost and cost effectiveness of a risk‐stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India. Methods The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Ch...

Full description

Saved in:
Bibliographic Details
Published in:Cancer medicine (Malden, MA) MA), 2023-02, Vol.12 (3), p.3499-3508
Main Authors: Mungle, Tushar, Das, Nandana, Pal, Saikat, Gogoi, Manash Pratim, Das, Parag, Ghara, Niharendu, Ghosh, Debjani, Arora, Ramandeep Singh, Bhakta, Nickhill, Saha, Vaskar, Krishnan, Shekhar
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Cancer therapies
Chemotherapy
Child
Childhood
Children
Clinical trials
Costs
cost‐effectiveness
Cytogenetics
Electronic medical records
Health Care Costs
Hospitals
Humans
Leukemia
low‐middle income countries
Lymphocytes B
Lymphocytes T
Patients
pediatric acute lymphoblastic leukemia
Pediatrics
Pharmacy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Retrospective Studies
risk‐stratified therapy
treatment cost
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background To evaluate the treatment cost and cost effectiveness of a risk‐stratified therapy to treat pediatric acute lymphoblastic leukemia (ALL) in India. Methods The cost of total treatment duration was calculated for a retrospective cohort of ALL children treated at a tertiary care facility. Children were risk stratified into standard (SR), intermediate (IR) and high (HR) for B‐cell precursor ALL, and T‐ALL. Cost of therapy was obtained from the hospital electronic billing systems and details of outpatient (OP) and inpatient (IP) from electronic medical records. Cost effectiveness was calculated in disability‐adjusted life years. Results One hundred and forty five patients, SR (50), IR (36), HR (39), and T‐ALL (20) were analyzed. Median cost of the entire treatment for SR, IR, HR, and T‐ALL was found to be $3900, $5500, $7400, and $8700, respectively, with chemotherapy contributing to 25%–35% of total cost. Out‐patient costs were significantly lower for SR (p 
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.5140